X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2551) 2551
Publication (189) 189
Book Review (53) 53
Book Chapter (50) 50
Patent (10) 10
Dissertation (3) 3
Conference Proceeding (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1774) 1774
oncology (1451) 1451
female (1344) 1344
index medicus (921) 921
first-line therapy (890) 890
middle aged (871) 871
aged (826) 826
chemotherapy (749) 749
adult (724) 724
male (656) 656
antineoplastic combined chemotherapy protocols - therapeutic use (641) 641
breast neoplasms - drug therapy (641) 641
treatment outcome (630) 630
first-line treatment (461) 461
cancer (434) 434
postmenopausal women (427) 427
breast cancer (407) 407
first-line (357) 357
care and treatment (332) 332
first-line chemotherapy (330) 330
antineoplastic combined chemotherapy protocols - adverse effects (318) 318
breast neoplasms - pathology (312) 312
aged, 80 and over (287) 287
tamoxifen (279) 279
phase-iii (277) 277
therapy (271) 271
disease-free survival (268) 268
neoplasm metastasis (266) 266
antineoplastic agents - therapeutic use (253) 253
paclitaxel (248) 248
randomized-trial (248) 248
trial (241) 241
pharmacology & pharmacy (239) 239
neoplasm staging (238) 238
metastasis (236) 236
double-blind (235) 235
survival (231) 231
anastrozole (229) 229
cisplatin (227) 227
medicine & public health (224) 224
lung neoplasms - drug therapy (222) 222
drug therapy (219) 219
aromatase inhibitors (210) 210
drug administration schedule (207) 207
combination (205) 205
efficacy (205) 205
phase-ii trial (203) 203
prognosis (201) 201
survival analysis (196) 196
docetaxel (194) 194
carcinoma (193) 193
carcinoma, non-small-cell lung - drug therapy (183) 183
research (182) 182
antineoplastic agents, hormonal - therapeutic use (181) 181
deoxycytidine - analogs & derivatives (178) 178
hematology, oncology and palliative medicine (173) 173
fluorouracil - administration & dosage (172) 172
clinical trials as topic (171) 171
megestrol-acetate (168) 168
analysis (167) 167
clinical trials (167) 167
colorectal neoplasms - drug therapy (167) 167
fluorouracil (166) 166
endocrine therapy (159) 159
metastatic breast cancer (159) 159
retrospective studies (158) 158
randomized trial (157) 157
carboplatin (156) 156
multicenter (155) 155
oxaliplatin (154) 154
survival rate (152) 152
bevacizumab (151) 151
letrozole (151) 151
tamoxifen - therapeutic use (147) 147
antineoplastic combined chemotherapy protocols - administration & dosage (146) 146
deoxycytidine - administration & dosage (143) 143
gemcitabine (142) 142
postmenopause (141) 141
randomized controlled trials as topic (140) 140
disease progression (136) 136
health aspects (136) 136
vinorelbine (136) 136
open-label (135) 135
phase-iii trial (135) 135
capecitabine (132) 132
5-fluorouracil (129) 129
follow-up studies (129) 129
paclitaxel - administration & dosage (128) 128
vinblastine - analogs & derivatives (128) 128
aromatase inhibitors - therapeutic use (126) 126
colorectal cancer (126) 126
chemotherapy, adjuvant (117) 117
irinotecan (116) 116
drug therapy, combination (115) 115
breast neoplasms - metabolism (114) 114
cisplatin - administration & dosage (114) 114
first line (114) 114
vinblastine - administration & dosage (114) 114
leucovorin (113) 113
respiratory system (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2449) 2449
German (71) 71
French (35) 35
Chinese (26) 26
Russian (15) 15
Korean (10) 10
Polish (6) 6
Hungarian (3) 3
Slovenian (2) 2
Spanish (2) 2
Indonesian (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 95, pp. 93 - 101
For hormone receptor–positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines... 
First-line treatment | Aromatase inhibitor-sensitive | Hormone receptor–positive HER2-negative metastatic breast cancer | Care and treatment | Cancer patients | Chemotherapy | Breast cancer | Metastasis | Hormones | Epidemiology | Cancer | Life Sciences | Human health and pathology
Journal Article
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2018, Volume 21, Issue 1, pp. 84 - 95
Journal Article
Journal Article
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2014, Volume 143, Issue 3, pp. 459 - 467
Journal Article
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2016, Volume 32, pp. 84 - 90
Abstract Background Currently only a few studies compare sequential and concomitant non-bismuth Helicobacter pylori therapies referring to high antibiotic... 
Internal Medicine | H. pylori treatment | Sequential treatment | First line | Concomitant treatment | Metronidazole resistance | Clarithromycin resistance | 14-DAY TRIPLE | 1ST-LINE TREATMENT | MULTICENTER | METAANALYSIS | REGIMEN | STANDARD TRIPLE THERAPY | RATES | MEDICINE, GENERAL & INTERNAL | INFECTION | HYBRID THERAPY | DURATION | Esomeprazole - administration & dosage | Humans | Middle Aged | Carbon Isotopes | Drug Resistance, Bacterial | Male | Helicobacter Infections - pathology | Helicobacter pylori | Peptic Ulcer - microbiology | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Female | Helicobacter Infections - metabolism | Urea - metabolism | Amoxicillin - administration & dosage | Drug Therapy, Combination | Dyspepsia - drug therapy | Metronidazole - administration & dosage | Breath Tests | Dyspepsia - microbiology | Pyloric Antrum - pathology | Biopsy | Aged | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Clinical trials | Drug resistance in microorganisms | Clarithromycin | Helicobacter Infections/drug therapy | Peptic Ulcer/drug therapy | Proton Pump Inhibitors/administration & dosage | Helicobacter Infections/pathology | Peptic Ulcer/microbiology | Tissues and Organs | Life Sciences | Esomeprazole/administration & dosage | Hépatology and Gastroenterology | Pyloric Antrum/pathology | Anti-Bacterial Agents/administration & dosage | Dyspepsia/microbiology | Helicobacter Infections/metabolism | Bacteriology | Clarithromycin/administration & dosage | Urea/metabolism | Metronidazole/administration & dosage | Microbiology and Parasitology | Human health and pathology | Amoxicillin/administration & dosage | Dyspepsia/drug therapy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 5, pp. 435 - 444
The combination of anastrozole and fulvestrant — which interfere with estrogen signaling by distinct mechanisms — increases progression-free and overall... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | TAMOXIFEN | DOUBLE-BLIND | RANDOMIZED-TRIAL | ENDOCRINE THERAPY | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | HORMONAL-THERAPY | FIRST-LINE THERAPY | Triazoles - administration & dosage | Triazoles - adverse effects | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Estradiol - adverse effects | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Estradiol - administration & dosage | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Cross-Over Studies | Disease-Free Survival | Estrogen Antagonists - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Estrogen Antagonists - adverse effects | Breast Neoplasms - mortality | Aged | Nitriles - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Breast cancer | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Fulvestrant | Statistical analysis | Anastrozole | Estrogen receptors | Tamoxifen | Cancer therapies | Survival | Patients | Post-menopause | Metastases | Chemotherapy | Womens health | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article